2018
DOI: 10.1016/j.atherosclerosis.2018.04.036
|View full text |Cite
|
Sign up to set email alerts
|

Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
17
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 27 publications
(18 citation statements)
references
References 29 publications
1
17
0
Order By: Relevance
“…In addition, the quantification of non-cholesterol sterols is divided between FID and MS detection 15,20,21) . GC/MS method with selective ion monitoring (SIM) and LC/MS-MS are used worldwide 22) , but in Japan, the GC method with FID is commonly used in clinical studies 9,12,23) . The quantification of non-cholesterol sterols is divided between GC with FID and MS detection with SIM, and currently, considerable variability exists between measurement techniques 21) .…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition, the quantification of non-cholesterol sterols is divided between FID and MS detection 15,20,21) . GC/MS method with selective ion monitoring (SIM) and LC/MS-MS are used worldwide 22) , but in Japan, the GC method with FID is commonly used in clinical studies 9,12,23) . The quantification of non-cholesterol sterols is divided between GC with FID and MS detection with SIM, and currently, considerable variability exists between measurement techniques 21) .…”
Section: Resultsmentioning
confidence: 99%
“…tive effect on clinical outcomes in the high sitosterol subset (≥ 2.2 µg/mL) of dyslipidemic patients with acute coronary syndrome 12) .…”
mentioning
confidence: 99%
“…19,20 This concept is based on findings in "sitosterolemia," 21 on genetic association studies in the general population, 22,23 epidemiological observation studies 24,25 and, most importantly, results from prospective randomized trials. 26,27 Findings in "4S" revealed that patients who were characterized by high cholesterol absorption did not benefit from statin treatment. 26 On the other hand, HIJ-PROPER demonstrated that only patients with high markers of cholesterol absorption benefit from ezetimibe treatment.…”
Section: Discussionmentioning
confidence: 99%
“…In our original study, we suggested that aggressive lipid-lowering therapy with ezetimibe had a positive effect on clinical outcomes in the high sitosterol subset (sitosterol level > 2.2 μg/mL) of ACS patients with dyslipidemia, but not in the low sitosterol subset (sitosterol level < 2.2 μg/mL) [15,16]. Lower levels of HDL-C at 3-month followup were independent predictors of primary endpoint in patients with higher sitosterol at baseline (HR, 1.50, 95% CI, 1.07-2.10, p = 0.02) (Supplemental Table 5).…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, although observational and interventional clinical studies have examined the value of HDL-C as a prognostic predictor, there is considerable variation in the results [5][6][7][8][9][10][11][12][13]. We previously published the results of the Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER) study, a randomized controlled trial that tested the efficacy of intensive lipid-lowering therapy and compared it with conventional lipid-lowering therapy in patients with acute coronary syndrome (ACS) [14,15]. The utility of HDL-C in ACS patients receiving conventional lipid-lowering therapy or intensive lipid-lowering therapy as a predictor of cardiovascular events has not been examined.…”
Section: Introductionmentioning
confidence: 99%